DSM has entered an agreement to make an equity invescalcium citrate 1200 mg with vitamin dtment isolgar calcium citrate with vitamin dn Amyris.###The two companies will also develop products for the global health and nutrition markets (including vitamins and other nutcitracal 630 mgritional ingredients).###Amyris’ technology supports DSM’s strategic markets in health, nutrition, and materials as well as a growing consumer shift to (bio-) natural-like products bariatric calcium citrate with vitamin dderived from sustainable sources.###For Amyris, DSM’s channels and market access and understanding in selecting the right products for the animal nutrition, human nutrition, and consumer health markets provide strategic value.###Equity investment###DSM will make an initial equity investment in Amyris of US$25 million, translating into a shareholding of about 12%.###Subject to the satisfaction of certain conditions, DSM may invest an additional US$25 million in Amyris.###As part of this investment, DSM will gain one board seat upon the closing of each tranche.###“Amyris has a unique yeast-based strain engineering platform that is very complementary to DSM’s capabilities in this area and will create great synergy with DSM’s know-how in fermentation, downstream process development and large-scale manufacturing,” said Chris Goppelsroeder, president and CEO of DSM Nutritional Products.#iron fumarate supplements##“Working closely together with Amyris and leveraging DSM’s route-to-market, will accelerate our innovation towards cost-effective, fermentation-based processes for both existing and new products.”